“Combination of axitinib and dasatinib for anti-cancer activities in two prostate cancer cell lines”, Bangladesh J Pharmacol, vol. 11, no. 1, pp. 130–137, Dec. 2015, doi: 10.3329/bjp.v11i1.24149.